Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 30, 2019 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies

SAN DIEGO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
September 18, 2019 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development...
September 12, 2019 00:53 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Pricing of Public Offering of Common Stock

SAN DIEGO, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development...
September 11, 2019 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development...
September 03, 2019 08:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces FDA Clearance of IND Application for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy

FT596 Product Candidate Derived from Clonal Master iPSC Line Engineered with Three Anti-Tumor Functional Components Designed to Overcome CD19 Antigen Escape and Improve Durability of Response by...
August 29, 2019 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Present at 2019 Wells Fargo Healthcare Conference

SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
August 14, 2019 08:00 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces Issuance of Foundational U.S. Patent Covering iPSC-derived CAR T Cells

SAN DIEGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
August 06, 2019 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Operational Progress

No FT500 DLTs Reported at Second Cell Dose Level in Monotherapy Arm or at First Cell Dose Level in Checkpoint Inhibitor Combination Arm in Solid Tumor Study Successfully Completed FT516 GMP...
July 30, 2019 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2019 Financial Results

SAN DIEGO, July 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
July 17, 2019 16:01 ET | Source: Fate Therapeutics, Inc.

Fate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors

SAN DIEGO, July 17, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...